Reminder: You are viewing our sharing site. Content may differ from our live site.
Skip to main content

# Psoriasis - Whole blood and components

## Essential information

Includes

  Psoriatic arthritis

Obligatory

  Must not donate if:

  1. Has ever taken etretinate (Tigason®).
  2. Less than 36 months from the last dose of acitretin (Neotigason®).
  3. Less than 6 months from the last dose of any treatment that may affect the immune system.
  4. Generalised or severe.
  5. There is secondary infection.
Discretionary
  1. If mild, the venepuncture site is unaffected and only using topical treatment, accept.
  2. If the donor:
     1. Has been established on oral treatment for their disease with only 1 of the following drugs:
        1. Methotrexate
        2. Sulfasalazine
        3. Hydroxychloroquine
        4. Azathioprine, and
     2. Their disease is controlled by medication, and
     3. The dose of the drug has not increased in the previous 6 months, and
     4. The venepuncture site is not affected, and
     5. The donor is well,
        accept.
  3. If the donor:
     1. Is receiving PUVA or UVA therapy for their skin disease, and
     2. Their disease is controlled, and
     3. The venepuncture site is not affected, and
     4. The donor is well,
        accept.

## Supporting information

See if relevant
  - Autoimmune disease
  - Monoclonal antibody therapy and other biological modalities
  - Steroid therapy
Additional information

  Psoriasis is primarily a skin condition caused by an autoimmune process. Sometimes the disease is treated with powerful drugs and/or ultraviolet radiation to suppress the underlying autoimmune process. This may be with treatment with PUVA, methotrexate, ciclosporin, hydroxycarbamide etc. and this may alter the body's defence mechanisms to infection.

  Etretinate (Tigason®) and acitretin (Neotigason®) can cause birth defects in babies exposed to them while inside the womb. It is important to allow time for the drug to be cleared from the blood of a donor. It takes longer to clear some drugs than others.

Reason for change:
  The text has been further updated to ensure consistency with other DSG references to immunosuppression.
Version details:

  WB-DSG Edition 203 Release 74 (26 November 2024)

BETA

This website recently launched. Help us improve it by giving your feedback (opens in new tab)